This study is testing a treatment called lutetium (177Lu) vipivotide tetraxetan (also called AAA617) for men with a type of prostate cancer that has small cancer spots, known as oligometastatic prostate cancer (OMPC). After their main tumor has been treated, but the cancer is still spreading, researchers want to see if this treatment helps control the cancer and improve the patients' quality of life.

Participants will need to pass some tests to be eligible, including special scans to check for cancer spots. They will receive Stereotactic Body Radiation Therapy (SBRT) for about three weeks. The study will last up to 6.5 years, with regular visits during the first cycles and every 16 weeks after that.

Key points:

• Participants will receive up to 4 cycles of the new treatment or just be observed.
• The study lasts approximately 6.5 years with regular check-ins.
• Participants must have had prostate cancer treatment before and show specific signs of cancer spread.